Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $22.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price boosted by Guggenheim from $20.00 to $22.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Canaccord Genuity Group cut their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $22.14.

Zevra Therapeutics Trading Up 4.7 %

NASDAQ ZVRA opened at $8.31 on Thursday. The company has a 50-day moving average of $7.93 and a 200-day moving average of $8.16. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a market cap of $449.70 million, a P/E ratio of -4.22 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million. As a group, equities analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Insiders Place Their Bets

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This trade represents a 17.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $82,530.00. Following the completion of the transaction, the executive vice president now directly owns 29,486 shares in the company, valued at approximately $231,759.96. The trade was a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 85,773 shares of company stock worth $674,176 in the last 90 days. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in shares of Zevra Therapeutics in the 4th quarter worth about $53,000. China Universal Asset Management Co. Ltd. bought a new stake in Zevra Therapeutics in the fourth quarter valued at about $94,000. XTX Topco Ltd bought a new stake in Zevra Therapeutics in the third quarter valued at about $94,000. Intech Investment Management LLC acquired a new stake in Zevra Therapeutics during the third quarter valued at approximately $95,000. Finally, Squarepoint Ops LLC lifted its holdings in Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after buying an additional 4,384 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.